Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Aug;76(2):E51-E52.
doi: 10.1002/hep.32516. Epub 2022 Apr 29.

Letter to the editor: Regression of liver fibrosis after bariatric operations: A glass two-third full rather than half empty

François Pattou  1   2   3   4   5 , Guillaume Lasailly  6 , Violeta Raverdy  1   2   3   4   5 , Robert Caiazzo  1   2   3   4   5 , Philippe Mathurin  6
Affiliations
Comment

Letter to the editor: Regression of liver fibrosis after bariatric operations: A glass two-third full rather than half empty

François Pattou et al. Hepatology. 2022 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

FP is the recipient of a grant from Agence National de la Recherche (Precinash ANR‐16‐RHUS‐006).

Figures

FIGURE 1
FIGURE 1
Estimates with 95% confidence intervals (error bars) of the proportions of participants with advanced fatty liver disease who experienced (A) NASH resolution, (B) improvement of liver fibrosis, and (C) resolution of advanced (bridging) fibrosis after bariatric operations at 1 and 5 years in Lassailly et al.[ 2 ] and between 1 and 11 years in Pais et al.[ 1 ]
See this image and copyright information in PMC

Comment on

References

    1. Pais R, Aron‐Wisnewsky J, Bedossa P, Ponnaiah M, Oppert J‐M, Siksik J‐M, et al. Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery. Hepatology. 2022;76:456–68.10.1002/hep.32358 - DOI - PubMed
    1. Lassailly G, Caiazzo R, Ntandja‐Wandji L‐C, Gnemmi V, Baud G, Verkindt H, et al. Bariatric surgery provides long‐term resolution of nonalcoholic steatohepatitis and regression of fibrosis. Gastroenterology. 2020;159(4):1290–301:e1295. - PubMed
    1. Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, et al. Obeticholic acid for the treatment of non‐alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo‐controlled phase 3 trial. Lancet. 2019;394:2184–96. - PubMed
    1. Vilar‐Gomez E, Martinez‐Perez Y, Calzadilla‐Bertot L, Torres‐Gonzalez A, Gra‐Oramas B, Gonzalez‐Fabian L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367–78.e5; quiz e14–5. - PubMed
    1. Aminian A, Al‐Kurd A, Wilson R, Bena J, Fayazzadeh H, Singh T, et al. Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy‐proven nonalcoholic steatohepatitis. JAMA. 2021;326(20):2031–42. - PMC - PubMed